Objectives Our aim was to study the relationships between total stent length (TSL) and long-term clinical outcomes after sirolimus-eluting stent (SES) implantation.
Multiple and long bare-metal stent (BMS) implantation is associated with a greater incidence of restenosis (1) (2) (3) , with diffuse in-stent restenosis (ISR) being the most common pattern. Diffuse ISR is, in turn, the major risk factor for malignant recurrent ISR, and, therefore, longsegment BMS implantation is associated with a poor clinical outcome (4, 5) . Randomized clinical trials and registries including complex coronary lesions have shown that sirolimus-eluting stents (SES) (Cypher, Cordis Corp.,
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Warren, New Jersey) reduce the need for revascularization therapy and provide clinical efficacy in routine practice, as compared with BMS (6 -13) . This remains true even in the context of the current trend to use a drug-eluting stent (DES) for full coverage of atherosclerotic lesions (i.e., stented segment length tends to be longer than the lesion length) (6) . SES implantation for long lesions with multiple stents is efficacious for reduction of restenosis (14 -17) ; however, long-term safety remains a concern, particularly with regard to late and very late thrombosis (18 -21) .
The relationships between total stent length (TSL) for DES and rates of late adverse events, including target lesion revascularization (TLR) and stent thrombosis (ST), have not been examined. Therefore, the objective of this study was to determine the 3-year cumulative incidences of clinical events including death, myocardial infarction, stroke, TLR, and ST according to TSL per lesion and per patient using data derived from the j-Cypher registry.
Methods
Study population. The design and 2-year outcome of the j-Cypher registry has been published previously (22) . In brief, the j-Cypher registry is a physician-directed multicenter registry of consecutive patients undergoing SES implantation at 37 centers in Japan. The study protocol was approved by the relevant review boards or ethics committees in the participating centers (22) . Written informed consent for enrollment in the registry was obtained from all patients.
Consecutive patients undergoing percutaneous coronary intervention (PCI) were registered in the PCI log form by technical staff at each center, and more than 50% of the case report forms were audited by the clinical research coordinators (22) in the data management center. Entry of detailed baseline and follow-up data for patients undergoing at least 1 SES implantation was performed via the Internet. Follow-up data were obtained from hospital charts or by contacting patients or referring physicians at 30 days, 6 months, and 1 year after the procedure, and yearly thereafter. Upon reports of important clinical events such as death, myocardial infarction, and ST, original source documents were requested to be sent to the data center, and the events were evaluated by the clinical events committee (22) .
Between August 2004 and November 2006, a total of 15,155 patients were enrolled in the registry from 29,555 consecutive patients undergoing PCI. SES implantation rates varied markedly among centers, with a median rate of 53% and a range of 16% to 92%. After exclusion of 2,331 patients who were registered more than once due to PCI for restenosis or new lesions, 12,824 patients were newly enrolled in the registry. Among 19,675 target lesions, 17,050 were treated exclusively with SES. Treatment for the remaining 2,625 lesions included BMS (1,259 lesions), a combination of SES and other stent types (495 lesions), other DES (60 lesions), nonstent PCI (672 lesions), failed procedures (139 lesions), and data not available (10 lesions). Finally, 10,773 patients who were exclusively treated with SES were identified as the population for the current analysis.
In this subanalysis of the j-Cypher registry, the patients and lesions were each grouped based on quartiles. For perpatient data for TSL, the lower, median, and upper borders of quartiles of TSL were 23, 36, and 54 mm, respectively, and for per-lesion data these borders were 18, 23, and 33 mm, respectively. Based on these data, there were 4 total stent length groups each per patient (TSL-P) and per lesion (TSL-L), respectively ( Fig. 1 ).
Lesion and patient evaluation.
Coronary angiographic parameters including reference vessel diameter, percentage stenosis diameter, and lesion length were assessed in each participating center by either visual assessment or quantitative angiography. A lesion was defined as the area covered by a single stent or multiple overlapping stents. When 2 stents were placed without overlap, the 2 treated areas were regarded as 2 separate lesions. When multiple overlapping stents were placed from the left main coronary artery to the left anterior descending coronary artery, these areas were also regarded as 2 separate lesions, despite placement of overlapping stents. Lesions located within 3 mm from the ostium were regarded as ostial lesions.
Death was regarded as cardiac in origin unless an obvious noncardiac cause could be identified. Myocardial infarction was adjudicated according to the definition in the ARTS (Arterial Revascularization Therapy Study) (23) . TLR was defined as either PCI or coronary artery bypass graft (CABG) surgery due to restenosis or thrombosis of the target lesion, including proximal and distal edge segments. ST was defined according to the Academic Research Consortium definition (24) . Academic Research Consortium definite ST was used as the end point for ST in this study (22) . The recommended antiplatelet regimen consisted of aspirin (Ն81 mg daily) indefinitely and thienopyridine (200 mg ticlopidine or 75 mg clopidogrel daily) for at least 3 months. The duration of dual antiplatelet therapy was left to the discretion of each attending physician. In this study, cumulative 3-year rates of TLR were evaluated based on the TSL-P and TSL-L groupings; the cumulative 3-year incidence of definite ST was also evaluated in the same groups, while the cumulative 3-year incidence of death/myocardial infarction was evaluated in the TSL-P groups (i.e., at the patient level only because the definitions included events unrelated to the lesions per se). Statistical analysis. Discrete variables are reported as numbers and percentages and continuous variables as means Ϯ SD. Categorical variables were compared with the chisquare test, while continuous variables were compared using the Student t test. Clinical event rates at 1, 2, and 3 years were compared by chi-square test. Cumulative incidences were estimated by the Kaplan-Meier method, and differences were assessed with the log-rank test.
The longest TSL-P group was considered as a risk factor for clinical outcomes, and the other 3 groups were combined as 1 comparison group. We used the Cox proportional hazard model to estimate hazard ratios (HRs) and their 95% confidence intervals (CIs) for the longest TSL-P group compared with the comparison group. Because the length of the stent was significantly associated with conditions of patients, we developed a propensity score for the longest TSL-P using logistic regression model, with the longest TSL-P as a response variable and the 16 variables (age, sex, body mass index, ST-segment elevation myocardial infarction, acute coronary syndrome, heart failure, prior PCI, prior CABG, prior myocardial infarction, prior stroke, peripheral artery disease, hemodialysis, estimated glomerular filtration rate Ͻ30 ml/min without hemodialysis, hypertension, current smoking, diabetes mellitus with insulin therapy) as explanatory variables. We developed Cox proportional hazard models to estimate the adjusted HRs for clinical events with variables of the longest TSL-P, propensity score, and the 16 variables mentioned in the preceding text. We used SAS version 9.1 (SAS Institute Inc, Cary, North Carolina). Values of p Ͻ 0.05 were considered statistically significant. Table 1 , top. Age, sex, or proportions of individuals with acute coronary syndrome at presentation, ST-segment elevation myocardial infarction, prior myocardial infarction, and hemodialysis status did not differ significantly 
Results

Patient characteristics. Patient characteristics are shown in
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Shirai et al. Multiple SES Implantation among the 4 groups. However, patients in group Q4 had significantly higher incidences of diabetes (with or without insulin therapy), smoking habit, prior stroke, peripheral vascular disease, prior heart failure, poor left ventricular function (ejection fraction Ͻ40%), and multivessel disease compared with those in the other 3 groups. The number of treated lesions increased according to TSL per patient. The proportion of patients with thienopyridine use Ն1 year increased with increasing TSL per patient. Lesion characteristics. Lesion characteristics are listed in Table 1 , bottom. Proportions of adverse lesion morphologies, such as total occlusion and ostial or severely calcified lesions, increased according to TSL per lesion. Minimal stent size was smallest in group QD. In group Continuous variables were expressed as mean value Ϯ SD.
ACS ϭ acute coronary syndrome; CABG ϭ coronary artery bypass grafting; eGFR ϭ estimated glomerular filtration rate; LAD ϭ left descending coronary artery; LCX ϭ left circumflex coronary artery;
LMCA ϭ left main coronary artery; PCI ϭ percutaneous coronary intervention; RCA ϭ right coronary artery; STEMI ϭ ST-segment elevation myocardial infarction.
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Multiple SES Implantation QA, the left circumflex coronary artery was a more frequent site of stent implantation while the left descending coronary artery and right coronary artery were less frequent sites compared with the other groups. Cumulative 3-year clinical outcomes. Cumulative incidences of death, cardiac death, myocardial infarction, stroke, TLR, and definite ST are listed in Table 2 (Fig. 2B) .
Cumulative 3-year rates of definite ST, and composite of death and myocardial infarction. The 3-year definite ST rates in the TSL-L groups were 0.60% in QA; 0.54% in QB; 0.79% in QC; and 0.89% in QD (Fig. 3A ). There were no significant differences in definite ST rates among the quartiles of TSL-L. In contrast to the per-lesion data, the cumulative 3-year definite ST rates in the TSL-P groups were 0.69% in Q1; 0.96% in Q2 The incidences of TLR rates in both patient and lesion level were increasing remarkably (log-rank p Ͻ 0.0001 in TSL-P and TSL-L) according to total stent length before adjustment for baseline characteristics. (Fig. 3B) . The ST rate in group Q4 was significantly higher than that in group Q1.
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The incidence of composite of death and myocardial infarction also increased according to increases in TSL per patient (Fig. 4) . HRs of clinical events before and after adjustment are shown in Table 3 . TLR and definite ST rate in Q4 remained significantly higher than in other stent length groups; however, death and myocardial infarction rate in Q4 was not statistically significant after adjustment for baseline characteristics.
Discussion
Although the efficacy and safety of multiple DES implantation for long coronary lesion treatment has been the subject of previous reports (15) (16) (17) , the follow-up periods There were no significant differences in definite ST rates in lesion level data according to total stent length (B). However, the incidences of definite ST in the longest total stent length group per patient, group Q4, was significantly higher than that in the shorter stent length group (A). Abbreviations as in Figure 2 . Estimated composite of death and myocardial infarction (MI) rates in total stent length per patient (TSL-P). Cumulative 3-year incidences of composite of death and MI increased significantly according to the increase in TSL-P before adjustment for baseline characteristics. CI ϭ confidence interval; HR ϭ hazard ratio.
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Multiple SES Implantation were usually limited to 6 to 12 months, and the sample sizes were generally small. This is the first publication based on a large population registry (number of patients Ͼ10,000) with long-term (up to 3 years) follow-up and outcome data analyzed across different stent lengths.
At 3-year follow up, increases in TSLs both per lesion and per patient were associated with incremental increase in TLR rates, while only TSL per patient was significantly associated with ST in unadjusted and adjusted data analyses. The incidences of composite of death and myocardial infarction also increased according to increased TSL per patient, however, there were no significant differences in the adjusted risk of composite of death and myocardial infarction according to the TSL-P.
Long and multiple BMS stent implantation is associated with increased restenosis and ST rates (1-4), whereas SES implantation has been shown to reduce restenosis and the need for revascularization in several randomized clinical trials and large registries (6 -17) . Consistent with previous reports (25, 26) , long and multiple SES implantation is associated with increased risks of restenosis and need for revascularization in this study, regardless of evaluation based on TSL per lesion or per patient. However, the frequency of repeat revascularization was lower compared with BMS implantation (6 -9) , despite the potential damage to the vessel wall and the high metal density.
However, the 3-year TLR rates were as high as 21.2% in group Q4 (TSL per patient 56 to 293 mm) and 15.6% in group QD (TSL per lesion 34 to 150 mm). This result is consistent with the finding in the SYNTAX (Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery) trial (27) that the rate of the major adverse cardiac events increased as the SYNTAX score increased. Therefore, we should admit that the complex procedures with extensive coverage of the coronary artery with SES are associated with substantial risk of repeated procedures. When these types of complex procedures are planned, the risk and the benefit against CABG surgery should be seriously assessed. Also, the recently reported FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) trial result suggested that PCI guided by physiologic lesion assessment in patients with multivessel disease resulted in less lesions treated and improved clinical outcome (28) . Our observation is in line with this FAME trial result.
While inhibition of cellular proliferation results in reduced neointimal hyperplasia and lower restenosis rates with SES, it may also delay endothelialization of the stent surface and increase the risk of ST. For instance, in the Bern and Rotterdam study, ST was reported to occur at a continuous rate of 0.4% to 0.6% per year for up to 4 years without diminution (29) . The mechanism underlying late thrombotic events has not been fully elucidated, but several hypotheses have been proposed, including impaired reendothelialization from angioscopic (30) or autopsy findings (31), hypersensitivity to polymers (32) , and nonresponsiveness to thienopyridine and aspirin (33) . Premature discontinuation of dual antiplatelet therapy has been associated with a higher incidence of ST, and this has led to the recommendation of therapy with aspirin and thienopyridine for at least 12 months (34) . However, in a recent observational study based on the j-Cypher registry, Kimura et al. (22) reported an annual incidence of definite ST of 0.2% in Japan, with no apparent clinical benefit of thienopyridine beyond 6 months after SES implantation. In our analysis, the incidence of definite ST was higher in the long stent group despite higher rates of thienopyridine use for more than 1 year. Optimal duration of dual antiplatelet therapy in patients undergoing PCI with extensive metal coverage is yet to be defined.
Previous data have demonstrated that stent length is a risk factor for acute and late ST (35, 36) and major adverse cardiac events, including a meta-analysis of 10 randomized studies that met the criteria of 9 to 12 months follow-up and antiplatelet therapy of only 2 to 3 months. Orlic et al. (37) reported that stent length per lesion and per patient are powerful indicators for major adverse cardiac events in treatment of multivessel disease with SES implantation; however, this report also had a short follow-up period of 6 months. Data from the Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivo) (38) and the Israeli arm of the e-Cypher registry (39) also show that stent length is an independent predictor of subacute and late ST for up to 3 years. In the second of these 2 analyses, stent length was used to denote the stent length per lesion, but the results differ from ours since stent length per lesion was not associated with a risk for ST. The long stent implanted group had several adverse risks affecting long-term clinical events; therefore, the incidences of death and myocardial infarction through 3 years were significantly increased according to increase TSL-P.
The SYNTAX trial showed an ST rate of 3.3% after 1 year (35) . In this trial, the mean TSL was 86.1 mm with 4.6 stents used to cover 3.6 lesions/patient. The 3.3% ST rate at 1 year suggests that complex procedures with implantation of longer and multiple stents to treat multivessel disease may be associated with an increased risk for ST. Our data also documented higher ST rates in patients (group Q4) with the longest TSL, and ST rates increased with number of stents. However, the definite ST rate of 1.42% at 3 years in group Q4 in our patients with mean stent length of 80.0 mm is markedly lower than 3.3% rate at 1 year reported in the SYNTAX trial. The different ST rates in these studies could be due to ethnic differences, but the details remain to be determined. Study limitations. This study has several limitations. First, it was performed as a nonrandomized, observational, and single-arm study. The absence of the control group under- N T I O N S , V O L . 3 , N O . 2 , 2 0 1 0 going CABG makes it difficult to make any recommendation on the selection of coronary revascularization strategy. Second, in our current analysis, stent fracture, which is observed as an extension of stent length and causes refractory restenosis, was not analyzed. Third, clinically driven and angiographically driven TLR were not differentiated. Relatively high rates of follow-up angiography might exaggerate the differences in TLR rate across the quartiles of TSL.
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Conclusions
Overall, our results suggest that the use of long and multiple SES to fully cover a lesion was associated with a high incidence of TLR, but not associated with increased ST for up to 3 years. However, treatment of multiple lesions with extensive metal coverage of the coronary artery increased the risk of TLR and ST. Total stent length was not associated with an increasing risk of death and myocardial infarction after adjustment of baseline characteristics.
